Wall Street: “Let Me Buy Your Algorithm”

This 20-year trading veteran once created a stock algorithm so powerful, Wall Street tried to buy it from him. Now, he’s built a BRAND-NEW market-crushing algo… and it’s flashing a HUGE opportunity that’s set to move THIS MONDAY. [ad]

Get the full details here while there’s still time
From $10M to $225M+ And Still Climbing

RAD Intel’s current Reg A+ round remains open at $0.91 per share, though that price is scheduled to change. Over the past year, RAD Intel’s share price has increased from $0.55 to $0.91. Earlier participants, entering in 2024, invested at prices as low as $0.38

The company has grown from a $10M valuation at merger to $225M+ and is backed by 20k+ investors including multiple Fidelity funds. RAD Intel was also selected by the Adobe Design Fund and has secured recurring seven-figure enterprise contracts across Fortune 1000 brands.

Sales contracts doubled from 2024 to 2025*, and the NASDAQ ticker has been reserved: $RADI.

This round is 80% allocated. Shares now at $0.91 – invest before the round closes 4/30.

DISCLOSURE: This is a paid advertisement for RAD Intel’s Reg A+ offering and involves risk, including the possible loss of principal. Please read the offering circular and related risks at invest.radintel.ai.
Florida Is Testing New Alternative Pesticide

This company is moving toward a possible Nasdaq listing – and once that happens, the early window closes.

Before Wall Street prices it in, this company has already generated $6.4M in sales, placed Nature-Cide on Amazon.com, Walmart.com, and Kroger.com, and begun expanding into 41+ global markets.

Florida’s mosquito control districts-America’s most well-funded and influential-are independently testing Nature-Cide botanical pesticides, as this company pursues WHO pre-qualification for global public health adoption.

This is the gap before the bell.

Review the opportunity now – before Nasdaq plans unfold.

Disclosures: This is a paid advertisement for Med-X’s Regulation A+ Offering. Please read the offering circular at invest.medx-rx.com.
How Kodak is trying to turn around its business after teetering on bankruptcy

• Photography company Eastman Kodak has seen its fair share of financial struggles, but CEO Jim Continenza is determined to make it a success story.

Privacy Policy | Advertiser DisclosureDISCLAIMER: Stocks and options trading have large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the stocks and options markets. Don’t trade with money you can’t afford to lose. This is neither a solicitation nor an offer to Buy/Sell stocks or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed in this report. The past performance of any trading system or methodology is not necessarily indicative of future results. All trades, patterns, charts, systems, etc., discussed in this report are for illustrative purposes only and not to be construed as specific advisory recommendations. Information contained in this correspondence is intended for informational purposes only and was obtained from sources believed to be reliable. Information is in no way guaranteed. No guarantee of any kind is implied or possible where projections of future conditions are attempted.

Stockguru LLC (dba InvestingDistrict), 2563 cherry hill ln, Hermitage, PA 16148, United StatesYou may unsubscribe or change your contact details at any time.